Recent research, supported by Cure Parkinson’s, has demonstrated that some classes of diabetes medications can reduce the risk of developing Parkinson’s.

Currently, one in 15 people in the UK has Type 2 diabetes, and that number is increasing; the risk of developing Parkinson’s in a person’s lifetime is also growing. Therefore, it is important to try to understand the relationship between the two conditions, and whether Type-2 diabetes medications might, in turn, be able to slow the progression of Parkinson’s.


Latest updates

Liraglutide trial: results

Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and...

Liraglutide trial: results

Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and...

Diabetes dual agonist drugs for Parkinson’s

Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of...

The exenatide phase 3 study protocol

Researchers conducting the phase 3 'Exenatide PD3' clinical trial have published the protocol of the study, which outlines the details of the trial. Cure...

Further support for diabetes treatments for Parkinson’s

A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development...